ΒΒΕΠΑΓΓΕΛΜΑ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ (CV)ΤΙΚΗ ΕΜΠΕΙΡΙΑ ... ·...
Transcript of ΒΒΕΠΑΓΓΕΛΜΑ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ (CV)ΤΙΚΗ ΕΜΠΕΙΡΙΑ ... ·...
ΒΒΕΠΑΓΓΕΛΜΑ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ (CV)ΤΙΚΗ ΕΜΠΕΙΡΙΑ
ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ
Ονοματεπώνυμο Παπαδοπούλου Λευκοθέα
Διεύθυνση Κατοικίας 28ης Οκτωβρίου 18, Θεσσαλονίκη, ΤΚ 54642
Τηλέφωνα επικοινωνίας 2310-997636 (Τμήμα Φαρμακευτικής, ΑΠΘ)
Διεύθυνση Ηλεκτρονικού Ταχυδρομείου [email protected]
ΕΚΠΑΙΔΕΥΣΗ
Πτυχίο Διδακτορικό
Τμήμα Φαρμακευτικής, Α.Π.Θ. 1980
Φαρμακολογία, Τμήμα Φαρμακευτικής, Α.Π.Θ. 1991
ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΔΙΑΔΡΟΜΗ
1982 Διορισμός ως «Επιστημονικός Συνεργάτης» στο Τμήμα Φαρμακευτικής, ΑΠΘ 1993 Εκλογή σε θέση Λέκτορα, Τμήμα Φαρμακευτικής, ΑΠΘ 2004 Εκλογή σε θέση Επίκουρου Καθηγητή, Τμήμα Φαρμακευτικής, ΑΠΘ 2012 Εκλογή σε θέση Αναπληρωτή Καθηγητή, Τμήμα Φαρμακευτικής, ΑΠΘΕ Π ΙΣΤΟΣΕΛΙΔΑ: http://www.pharm.auth.gr/el/faculty/45
ΕΠΙΣΤΗΜΟΝΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ - ΕΠΙΤΕΥΓΜΑΤΑ
Εκπαιδευτική άδεια ως Post-Doctoral Research Fellow Απρίλιος 1996 -Νοέμβριος 1997 (20 μήνες) Department of Neurology, Ιούλιος 1998- Σεπτέμβριος 1998 ( 3 μήνες) College of Physicians and Surgeons, COLUMBIA UNIVERSITY in the City of New York, U.S.A.
AΠΟΜΟΝΩΣΗ ΚΑΙ ΤΑΥΤΟΠΟΙΗΣΗ ΤΟΥ ΑΝΘΡΩΠΙΝΟΥ SCO2 ΓΟΝΙΔΙΟΥ. ΚKατάθεση σε βάσεις δεδομένων:
Nucleotide: GenBank Accession number: F177385
P Protein: GenBank Accession number: OMIM:
AAF05313 ##604377
Reference Papadopoulou LC, et al (1999) Fatal infantile cardioencephalomyopathy with COX deficiency and
mutations in SCO2, a COX assembly gene. NATURE GENETICS, 23(3):333-337 (cited by 566).
ΜΕΛΟΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΠΙΤΡΟΠΩΝ
Member of Hellenic Society of Biochemistry and Molecular Biology
Member of the Mitochondria Research Society
Member of Greek Society of Pharmacology
Hellenic Proteomic Society
Hellenic Society of Gene Therapy and Regenerative Medicine
ΚΥΡΙΑ ΕΡΕΥΝΗΤΙΚΑ ΕΝΔΙΑΦΕΡΟΝΤΑ
Αλληλεπιδράσεις φαρμάκων και μοριακοί μηχανισμοί φαρμακολογικής και τοξικής δράσης
αντινεοπλασματικών φαρμάκων στο μυελό των οστών και το μυοκάρδιο.
Μοριακοί μηχανισμοί δράσης φαρμάκων επί της έκφρασης μιτοχονδριακών γονιδίων.
Η συμβολή των μιτοχονδρίων στους μοριακούς μηχανισμούς ελέγχου της απόπτωσης των κυττάρων.
Ανάλυση των μηχανισμών που διέπουν την τύχη του μιτοχονδριακού γονιδιώματος και ρόλος
μιτοχονδριακών και πυρηνικών γονιδίων στην παθογένεια νευρομυοεκφυλιστικών ασθενειών που
οφείλονται σε ελαττωματική λειτουργία της αναπνευστικής αλυσίδας.
Κλωνοποίηση και έκφραση πυρηνικών γονιδίων (COX assembly genes) σε βακτηριακά κύτταρα
καθώς και καθαρισμός και χαρακτηρισμός των παραγόμενων πρωτεϊνών, οι οποίες συμμετέχουν στη
μεταφορά χαλκού από το κυτταρόπλασμα στα μιτοχόνδρια, και πιο συγκεκριμένα στις υπομονάδες
του ολοενζύμου «οξειδάση του κυτοχρώματος c (COX) ».
Bιοτεχνολογική παραγωγή ανασυνδυασμένων πρωτεϊνών.
Ενδοκυτταρική μεταφορά ανθρώπινων ανασυνδυασμένων πρωτεϊνών [με παράλληλη στόχευση
οργανιδίων (μιτοχόνδρια)] μέσω της χρήσης της τεχνολογίας της Πρωτεϊνικής Μεταγωγής (PTD
Τεχνολογία), με απώτερο στόχο την «πρωτεϊνική θεραπεία» μονογονιδιακών ασθενειών
(μιτοχονδριακές ασθένειες – αιμοσφαιρινοπάθειες - θαλασσαιμίες)
Ραδιοεπισήμανση των βιοτεχνολογικά ανασυνδυασμένων πρωτεϊνών (μέσω της τεχνολογίας της
Πρωτεϊνικής Μεταγωγής) και μελέτη της βιοκατανομής τους σε πειραματόζωα
Aξιολόγηση της μιτοχονδριακής λειτουργίας – βιοενεργητικής (cell bioenergetics) σε κυτταρικές
καρκινικές σειρές - ρόλος σηματοδοτικών μονοπατιών στην παθογένεια του καρκίνου
Ανοσοθεραπεία του καρκίνου - CAR T Θεραπεία
Ανάπτυξη IVT-mRNAs, μέσω της PTD Τεχνολογίας, ως θεραπευτικών μορίων
ΕΚΠΑΙΔΕΥΤΙΚΟ ΕΡΓΟ - ΤΜΗΜΑ ΦΑΡΜΑΚΕΥΤΙΚΗΣ
Προπτυχιακές Σπουδές
ΔΙΔΑΣΚΑΛΙΑ Τοξικολογία 1999 -
Κλινική Φαρμακολογία και θεραπευτική 1999 -
Φαρμακολογία ΙΙ 2015-2018
Φαρμακευτική Βιοτεχνολογία 2015-2018
Φαρμακολογία Ι 2018- “ΑΡΙΣΤΕΙΑ στη ΔΙΔΑΣΚΑΛΙΑ”, Σχολή Επιστημών Υγείας, Α.Π.Θ., Ακαδημαϊκό έτος 2014-2015
Μεταπτυχιακές Σπουδές
ΕΠΙΣΤΗΜΟΝΙΚΗ ΥΠΕΥΘΥΝΟΣ της κατεύθυνσης «Φαρμακολογία και Θεραπευτική», από το 2015
ΕΡΕΥΝΗΤΙΚΟ ΕΡΓΟ
CITATIONS: 1303 (Google Scholar), Index h: 12
https://scholar.google.com/citations?view_op=new_articles&hl=el&imq=Papadopoulou+LC
https://www.ncbi.nlm.nih.gov/pubmed/?term=Papadopoulou+LC
ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ
ΑΝΑΛΥΣΗ ΤΩΝ ΑΛΛΗΛΕΠΙΔΡΑΣΕΩΝ ΑΝΘΡΑΚΥΚΛΙΝΩΝ -ΣΙΔΗΡΟΠΟΡΦΥΡΙΝΩΝ
ΣΤΟ ΑΙΜΟΠΟΙΗΤΙΚΟ ΣΥΣΤΗΜΑ (εκπονήθηκε υπό την επίβλεψη του καθηγητή κ. Αστέριου Σ. Τσιφτσόγλου)
ΕΠΙΣΤΗΜΟΝΙΚΑ ΑΡΘΡΑ (PAPERS)
1. Miliotou, AN and Papadopoulou LC. (2019) «IVT-mRNA CAR Therapy Development», in
Springer Nature. Accepted chapter in “Chimeric Antigen Receptor T Cells - Development and
Production”, to be published in the Lab Protocol Series: Methods in Molecular Biology. (INVITED)
2. Vizirianakis IS, Miliotou, A.N., Mystridis GA, Andriotis, EG, Andreadis I, Papadopoulou
LC, Fatouros DG. (2019) Tackling pharmacological response heterogeneity by PBPK modeling to
advance precision medicine productivity of nanotechnology and genomics therapeutics. Submitted for
publication. Under Submission in Expert Review of Precision Medicine and Drug Development.
(INVITED review)
3. Haido-Christina Pagoni, Stella Xylouri, Georgios Kaiafas, Marialena Lazou, Georgia
Bombola, Lefkothea Papadopoulou, Georgios Psomas and Dionysia Papagiannopoulou. (2019)
Synthesis and biological evaluation of organometallic rhenium tricarbonyl fluoroquinolones with
increased cytotoxicity against myeloid leukemia K-562 cells. Submitted for publication
4. Miliotou NA, Papadopoulou LC. (2018) CAR T-cell Therapy: A New Era in Cancer
Immunotherapy. Curr Pharm Biotechnol., 19(1):5-18. (INVITED review). (cited by 12)
5. Papadopoulou LC, Ingendoh-Tsakmakidis A, Mpoutoureli CN, Tzikalou LD, Spyridou ED,
Gavriilidis GI, Kaiafas GC, Ntaska AT, Vlachaki E, Panayotou G, Samiotaki M, Tsiftsoglou AS.
(2018) Production and Transduction of a Human Recombinant β-Globin Chain into Proerythroid K-
562 Cells To Replace Missing Endogenous β-Globin. Mol Pharm. Nov 12. [Epub ahead of print] [doi:
10.1021/acs.molpharmaceut.8b00857]
6. Kydonaki TE, Tsoukas E, Mendes F, Hatzidimitriou AG, Paulo A, Papadopoulou LC,
Papagiannopoulou D, Psomas G. (2016) Synthesis, characterization and biological evaluation of
(99m)Tc/Re-tricarbonyl quinolone complexes. J Inorg Biochem., 160:94-105.
(cited by 17)
7. Papadopoulou LC, Kyriazou ΑV, Bonovolias ID and Tsiftsoglou AS (2014) Imatinib inhibits
the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr–
Abl+ leukemia cells. Blood Cells, Molecules and Diseases, 53(1-2): 84-90.
(cited by 3)
8. Papadopoulou LC, Tsiftsoglou AS. (2013) The Potential Role of Cell Penetrating Peptides in
the Intracellular Delivery of Proteins for Therapy of Erythroid Related Disorders. Pharmaceuticals 6,
32-53. (INVITED review). (cited by 10)
9. Papadopoulou LC, Tsiftsoglou AS. (2011) Transduction of human recombinant proteins into
mitochondria as a protein therapeutic approach for mitochondrial disorders. Pharm Res.
Nov;28(11):2639-56. (INVITED review). (cited by 10)
10. Foltopoulou PF, Tsiftsoglou AS, Bonovolias ID, Ingendoh AT, Papadopoulou LC. (2010)
Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the
mitochondria of permanent cell lines and SCO2 deficient patient's primary cells. Biochim Biophys
Acta. Jun;1802(6):497-508. (cited by 17)
11. Bonovolias ID., Papadopoulou L.C. and Tsiftsoglou A.S. (2010) Assessing the effect of
Imatinib on the expression of genes involved in mitochondrial cell respiration in human K-562 CML
cells. Review of Clinical Pharmacology and Pharmacokinetics (Epitheorese Klinikes
Farmakologias and Farmakokinetikes), International Edition, 24: 123-124
12. Papadopoulou LC, Foltopoulou P.F., Tsiftsoglou AS (2010) Intracellular Delivery of
Recombinant Human Proteins into Mammalian cells as a Potential Therapeutic Approach. 10th
European Biological Inorganic Chemistry Conference (Eurobic10) Pages: 23-28
13. Zaverda C.G., Nentoudi K.A., Foltopoulou P.F., Tsiftsoglou A.S. and Papadopoulou L.C.
(2007) Bacterial production of recombinant human β-globin-TAT-HA peptide intended for targeted
delivery in thalassemic cells. Proceedings of The International Conference on Nanomedicine,
September 9-11, Chalkidiki, Greece, pp. 202-209
14. Papadopoulou L.C, Tsiftsoglou A.S., and Foltopoulou P.F. (2007) PTD-technology
complemented by combinatorial tag-cloning for bacterial production of recombinant human proteins
intended for intracellular delivery. Proceedings of The International Conference on Nanomedicine,
September 9-11, Chalkidiki, Greece, pp. 210-217
15. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC. (2006) Heme as key regulator of major
mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol Ther.
Aug;111(2):327-45. (INVITED review). (cited by 246)
16. Foltopoulou P.F., Tsiftsoglou A.S. and Papadopoulou L.C. (2005). Production of genetically
engineered TAT-Sco2 protein aimed for intracellular delivery into mitochondria: Implications to the
therapy of COX-deficient fatal infantile cardioencephalopathy. Review of Clinical Pharmacology and
Pharmacokinetics (Epitheorese Klinikes Farmakologias and Farmakokinetikes), Greek Edition, 23 (1):
106-107
17. Foltopoulou PF, Zachariadis GA, Politou AS, Tsiftsoglou AS, Papadopoulou LC. (2004)
Human recombinant mutated forms of the mitochondrial COX assembly Sco2 protein differ from wild-
type in physical state and copper binding capacity. Mol Genet Metab. Mar;81(3):225-36.
(cited by 27)
18. Clark KM, Brown TA, Davidson MM, Papadopoulou LC, Clayton DA. (2002) Differences
in nuclear gene expression between cells containing monomer and dimer mitochondrial genomes.
Gene. Mar 6;286(1):91-104. (cited by 12)
19. Sue CM, Karadimas C, Checcarelli N, Tanji K, Papadopoulou LC, Pallotti F, Guo FL,
Shanske S, Hirano M, De Vivo DC, Van Coster R, Kaplan P, Bonilla E, DiMauro S. (2000) Differential
features of patients with mutations in two COX assembly genes, SURF-1 and SCO2. Ann Neurol.
May;47(5):589-95. (cited by 137)
20. Papadopoulou L.C., Foltopoulou P.F., Tsiftsoglou A.S., Sue C.M., Tanji K., Bonilla E.,
Hirano M., DiMauro S. and Schon E.A. (2000). Mutations in Human SCO2, a nuclear COX assembly
gene, and their possible role in causing COX deficiency associated with fatal
cardioencephalomyopathy. Newsletter, 47:111-112.
21. Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S,
Walker W, Selby J, Glerum DM, Coster RV, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De
Vivo DC, Bonilla E, Hirano M, DiMauro S, Schon EA. (1999) Fatal infantile
cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene.
Nature Genetics Nov;23(3):333-7. (cited by 566)
22. Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS. (1999) Structural and
functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression
of cytochrome c oxidase II gene expression. Biochem Pharmacol. Mar 1;57(5):481-9.
(cited by 89)
23. Manfredi G, Thyagarajan D, Papadopoulou LC, Pallotti F, Schon EA. (1997) The fate of
human sperm-derived mtDNA in somatic cells. Am J Hum Genet. Oct;61(4):953-60.
(cited by 98)
24. Papadopoulou LC, Tsiftsoglou AS. (1996) Effects of hemin on apoptosis, suppression of
cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin
(adriamycin). Biochem Pharmacol. Sep 13;52(5):713-22. (cited by 47)
25. Papadopoulou LC, Tsiftsoglou AS. (1993). Mitochondrial cytochrome c oxidase as a target
site for daunomycin in K-562 cells and heart tissue. Cancer Res. 1993 Mar 1;53(5):1072-8.
(cited by 34)
26. Papadopoulou L.C. and Tsiftsoglou A.S (1993) Interactions of hemin and anthracyclines with
mitochondrial cytochrome c oxidase. J. Chemotherapy 5, Suppl. 1 May, 788-789.
27. Papadopoulou LC, Wheeler C, Tsiftsoglou AS. (1989) Possible role of mitochondrial
components in adriamycin-induced cytotoxicity of human leukemia cells. J Chemother. 1989 Jul;1(4
Suppl):1151-4.
28. Papadopoulou L.C., Wheeler C. and Tsiftsoglou A.S. (1988). Daunomycin-hemin
interactions: implications into the mechanism(s) of molecular action of anthracyclines on hemopoietic
cells and therapeutic significance. Newsletter, 27: 15-18.
Abstracts
1. Papadopoulou L.C. and Tsiftsoglou A.S. (1989). Mitochondrial hemoproteins as target sites
involved in cytotoxic action of daunomycin in dividing and nondividing cells. Proc. Amer. Assoc.
Cancer Res., 30: 561 (2234).
2. Vizirianakis I.S., Marcopoulou C., Kountourelis J.E., Papadopoulou L.C. and Tsiftsoglou
A.S. (1990). RNA methylation as a key-regulatory process in growth and differentiation of murine
erythroleukemia (MEL) cells: inhibition by N6-methyl-adenosine (N6meAdo). Proc. Amer. Assoc.
Cancer Res., 31:35 (206).
3. Papadopoulou L.C., Oikonomou-Antoniadou M. and Tsiftsoglou A.S. (1990). Analysis of
protective effects of hemin on adriamycin induced myelossuppression in rats. J. Cancer Res.Clin.
Oncol., 116 (Suppl., part I): 481 (A4.129.05).
4. Papadopoulou L.C. and Tsiftsoglou A.S. (1994). Hemin selectively prevents apoptosis and
partially reverses suppression of cytochrome c oxidase gene expression induced by adriamycin in
human leukemia K-562 cells. Thirteenth meeting of the European Association for Cancer
Research, Berlin, Germany, September 25-28, p 133.
5. Tsiftsoglou A.S., Papadopoulou L.C., Robinson S.H. and Wong W. (1995). Mechanisms by
which hemin counteracts adriamycin-induced myelossuppression. The International Symposium on
porphyrias and heme related disorders, June 28-July 2. The Scandinavian Journal of Clinical &
Laboratory Investigation, Vol. 55 (Suppl.223): No 40.
6. Papadopoulou L.C., Sue C.M., Davidson M., Tanji K., Nishino I., Shanske S., DeVivo D.C.,
Bonilla E., Hirano M., DiMauro S. and Schon E.A. (1999). Mutations in a human COX assembly
gene are associated with fatal cardioencephalomyopathy and COX deficiency. The Fourth Meeting
on Mitochondrial Pathology, Queens' College, Cambridge, U.K., 16-19 September, p. 167.
7. Glerum D.M., Papadopoulou L., Schon E. and Adams D. (1999). Characterization of hSCO2
mutations involved in cytochrome oxidase deficiency. In American Journal of Human Genetics
(October) Vol. 65, No. 4, pp. A236. 5720 South Woodlawn Ave, Chicago, Il 60637-1603 USA: Univ
Chicago Press.
8. Sue C.M., Karadimas C., Checcarelli N. et al. (2000) Comparison of clinical features in patients
with COX assembly gene mutations. Neurology 54 (7): A388 Suppl., 3 APR 11
9. Tsiftsoglou A.S., Pappas I., Vizirianakis I., Sidiropoulou A. and Papadopoulou L.C. (2001).
Μechanisms of differentiation and differentiation dependent – apoptosis (DDA) in Leukemic cells.
Oncology Research, 12: 273.
10. Foltopoulou P.F., Zachariadis G.., Tsiftsoglou A.S. and Papadopoulou L.C. (2002). Cloning,
expression and purification of the mitochondrial assembly protein Sco2, involved in the pathogenesis
of fatal infantile cardioencephalomyopathy. Epitheorese Klinikes Farmakologias and
Farmakokinetikes, International Edition, 16: 66.
11. Zaverda C.G., Foltopoulou P.F., Tsiftsoglou A.S. and Papadopoulou L.C. (2005)
Biotechnological production of human fused recombinant β-globin-TAT protein for intracellular
delivery in K562 cells: Alternative therapeutic approach of patients with βΟ–thalassemia. 12th
Panhellenic Pharmaceutical Congress, Athens, 14-16 May, 37:083
12. Foltopoulou P., Zaverda C., Nentoudi K., Tsiftsoglou A. and Papadopoulou L. (2006)
Production of human recombinant proteins Sco2 and beta-globin fused with PTDs for intracellular
targeting delivery. 31st FEBS Congress in “Molecules in Health and Disease”, June 24-29,
Instanbul, p370, PP-791a.
13. Kyriakidou H., Cieslak D., Papadopoulou L., Tsiftsoglou A., and Lazou A. (2006) Evaluation
of Doxorubicin-induced apoptosis in HepG2 cells. Hellenic Society for Biological Sciences.
Proceedings of 28th Scientific Conference, Ioannina, May, p.184.
14. Foltopoulou P.F., Nentoudi K.A., Zaverda C.G., Tsiftsoglou A.S. and Papadopoulou L.C.
(2006). Human recombinant proteins developed via combinatorial cloning and protein transduction
technology (PTD) are intended for intracellular delivery and protein therapy of metabolic disorders.
11th International Conference on “Differentiation Therapy and Innovative Therapeutics in
Oncology”, November 4-8, Versailles, France, p.42, P29.
15. Μarkou T., Iordanidou A., Cieslak D., Papadopoulou L., Tsiftsoglou A., and Lazou A.
(2008). Role of PI-3-K/GSK3 and MAPK signaling in doxorubicin-induced HepG2 apoptosis.
Apoptosis 2008, January, Luxembourg.
16. Foltopoulou P.F., Tsiftsoglou A.S., Bonovolias I.D., and Papadopoulou L.C. (2008).
Targeted delivery of recombinant fusion human mitochondrial TAT-Sco2-HA protein into mammalian
cells via PTD technology: a protein therapy approach for metabolic disorders. Joint Conference of the
33rd FEBS Congress/11th IUBMB Conference, FEBS JOURNAL, Vol: 275, pp: 195-195, JUN 28-
JUL 03, Athens, GREECE
17. Papadopoulou L.C, Foltopoulou P.F., Bonovolias I.D., and Tsiftsoglou A.S. (2009). Targeted
Intracellular Delivery of Human Recombinant Proteins into Mammalian Cells / Tissues as a potentially
Protein Therapeutic Approach: The case of Mitochondrial Sco2 protein. 6th International Conference
on Nanosciences & Nanotechnologies, 13-15 July, Thessaloniki, Greece, p.53
18. Tsiftsoglou A.S., Bonovolias I.D., and Papadopoulou L.C. (2009). Imatinib suppresses the
expression of Mitochondrial COX assembly SCO2 gene in human K-562 BCR-ABL (+) CML cells.
38th Annual Scientific Meeting of the ISEH-Society-for-Hematology-and-Stem-Cells, September
9-12, Athens, Greece EXPERIMENTAL HEMATOLOGY Vol: 37(9) pp: S47-S48
19. Papadopoulou L.C., Foltopoulou P.F. and Tsiftsoglou A.S. (2010). Intracellular Delivery of
Recombinant Human Proteins into Mammalian cells as a Potential Therapeutic Approach.
Proceedings (M622) of the 10th EUROBIC, June 22-26, Thessaloniki, Greece
20. Tsiftsoglou A.S., Bonovolias I.D., and Papadopoulou L.C. (2010). The p53/Sco2/COX
interactive pathway in mitochondria as a novel target for Imatinib in human K-562 Bcr-Abl(+) cells.
In MODERN TRENDS IN HUMAN LEUKEMIA & CANCER. XVIII. Wilsede meeting, June 19-
23, Germany
21. Gavriilidis G., Papadopoulou L.C., Tsiftsoglou A.S. (2012) Cloning, expression, purification
and biological activity of Human Soluble Stem Cell Factor (hs SCF) in E. Coli cells. 64th Congress
of the Hellenic Society of Biochemistry and Molecular Biology, December 2013, Athens, Greece
22. Papadopoulou LC. (2013) Protein transduction via PTD technology as a therapeutic approach
of mitochondrial disorders. 2nd international conference and Exhibition on neurology &
Therapeutics. June 17-19, Hilton Chicago/Northbrook, Chicago, USA
23. Papagiannopoulou D., Kaiafas G., Papadopoulou L. (2014) In vitro and in vivo evaluation of
TC-99m radiolabeled cell penetrating TAT-L-Sco2-HA mitochondrial protein. 65ο Panhellenic
Conference of HSBMB, 28-30 November, Thessaloniki.
24. Tsoukas E., Kydonaki T.E., Psomas G., Papagiannopoulou D, Papadopoulou LC.
Cytotoxicity of Re/Enrofloxacin complex in two different cancer cell lines (2016) 9ο Panhellenic
Congress of Pharmacology, 20-22 Μay, Electra Palace, Thessaloniki.
25. Papadopoulou L.C., Ingendoh-Tsakmakidis A, Mpoutoureli CN, Tzikalou LD, Gavriilidis GI,
Kaiafas GC, Ntaska AT, Spyridou ED, Zaverda C.G, Nentoudi K.A., Vlachaki E, Samiotaki M,
Panayotou G, Tsiftsoglou AS. (2017) Production and transduction of human recombinant TAT-β-
globin chain into K562 model system for thalassemias.14th International Conference on
Thalassemia and Other Haemoglobinopathies & 16th TIF Conference for Patients and Parents.
17-19 November, Thessaloniki, Greece.
26. Mavridou D.D., Gavriilidis G.I., L Papadopoulou L.C. (2018) Effects of imatinib and
dichloroacetate acid on cellular bioenergetics of Chronic Lymphocytic Leukemia cells. Short Oral
Presentation at the 10th Congress of the Hellenic Society for Basic and Clinical Pharmacology,
25-27 May, Ioannina, Greece.
27. Miliotou A.N., Laspa, D.G., Papadopoulou L.C. (2018) Cloning and expression of
recombinant human α-globin through PTD technology: Study of its intracellular transduction in K562
proerythroid cell culture. Poster presentation at the 10th Congress of the Hellenic Society for Basic
and Clinical Pharmacology, 25-27 May, Ioannina, Greece.
28. Miliotou A.N., Pappas I.S., Vizirianakis I.S., Papadopoulou L.C. (2018) Development of in
vitro transcribed SCO2 mRNA as novel therapeutic approach in a mitochondrial disorder, due to SCO2
mutations. Short Oral Presentation at the 69th Panhellenic Conference of the Hellenic Society for
Biochemistry and Molecular Biology (HSBMB), 23-25 November, Larisa, Greece.